Please assess the completion status of the following clinical trial:

Trial Title: A Study of Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* primary IgA nephropathy~* age 18-75 years~* proteinuria range from 0.75 to 3.5g/d even after three-month treatment by sufficient ACEi/ARB~* eGFR\>30ml/min/1.73m2~Exclusion Criteria:~* immune suppressive agent in recent one years~* crescent glomerulonephritis, might use immune suppressive agent~* chronic hepatic disease~* myocardial infarction~* malignant hypertension~* stroke~* malignant tumor~* retinopathy~* other contraindication of Hydroxychloroquine~* pregnancy and breastfeeding women~* life expectancy for less than 6 months~* in other clinical trials~* not suitable for the study judged by investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Hydroxychloroquine Sulfate (Type: ACTIVE_COMPARATOR): 200mg Bid (eGFR\>60 ml/min/1.73m2), 100mg Tid (eGFR45-59 ml/min/1.73m2), 100mg Bid (eGFR 30-44 ml/min/1.73m2) and supportive treatment
- Placebo (Type: PLACEBO_COMPARATOR): Placebo and supportive treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).